After kicking off March with the announcement of US Food and Drug Administration approval for two denosumab biosimilars, Sandoz has closed out April by revealing that it has secured a launch date of 31 May 2025 for the products through a litigation settlement with originator Amgen.
Sandoz early last month received an FDA nod for its Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) rivals to Amgen’s Xgeva and Prolia brands, representing the first denosumab biosimilars approved by the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?